January 2011

Common baldness could have its roots in a newly identified stem cell defect, a finding that could potentially lead to new hair-loss treatments down the road, a new study reveals. Researchers say they discovered that a cellular malfunction short-circuits the process by which hair follicle stem cells turn into hair-producing progenitor cells.

Ecron Acunova (EA), a leading CRO with presence in Europe and Asia announced a joint venture with Jamjuree Innovations Co. Ltd., (JJI) Thailand. JJI is a 100% subsidiary of Chulalongkorn University Intellectual Property Foundation and enjoys strong ties with the University’s Faculty of Medicine, including Clinical Research Center (Chula CRC). The joint venture CRO is based in Bangkok and will conduct clinical research in key South East Asian countries under the name Ecron Acunova Company Ltd (EACL). Dr.

Cell Biosciences, Inc., a provider of innovative protein analysis tools to life science researchers, today announced the launch of the latest addition to their premier line of next-generation imaging products, the FluorChem® M MultiFluor system. This new platform combines highly-sensitive quantitative detection of multicolor fluorescent Western blots with key ease-of-use features aimed at simplifying the laboratory imaging process.

Alembic Limited, with an established presence in the Indian pharma  industry has a proud, historical track record going back one hundred years. With a turnover in excess of Rs1000 crores today, Alembic Limited is one of India’s leading integrated pharmaceutical companies. We continue to enjoy leadership positions in antibiotics, anti-infective, anti-cough and also have significant worldwide presence in specialty therapeutic areas such as cardiology, neurology, diabetology, etc.

Arch Pharmalabs has gained recognition as a world-class provider of small molecule process chemistry, custom synthesis services and full life-cycle API and drug intermediates manufacture for the global pharmaceutical industry. Generating revenues of USD 200 million, our India-based offering is supported by 2,400 customer-centric Archers, eleven certified facilities (including cGMP-compliant, US FDA- and EDQM-approved sites) and two state-of-the-art Process Technology centres.

Arch Pharmalabs has gained recognition as a world-class provider of small molecule process chemistry, custom synthesis services and full life-cycle API and drug intermediates manufacture for the global pharmaceutical industry. Generating revenues of USD 200 million, our India-based offering is supported by 2,400 customer-centric Archers, eleven certified facilities (including cGMP-compliant, US FDA- and EDQM-approved sites) and two state-of-the-art Process Technology centres.

Franco-Indian Pharmaceuticals Pvt. Ltd., a name that stands for quality and innovation, is one of the major players in the Pharmaceutical Industry in India.
Our innovative, value added products improve the quality of life of people and ease their sufferings and help them to enjoy, longer, healthier and more productive lives.